Advertisement
MicroPhage will apply proceeds of its financing to complete the validationand launch preparation of their initial diagnostic products, which address thegrowing need for simple, rapid and highly accurate tests for hospital-acquiredinfections (HAIs), such as MRSA.
Advertisement
R. Gary Mesch, chairman of MicroPhage commented "MicroPhage investors areconfident the company will deliver badly needed diagnostic tools in the fightagainst MRSA and other HAIs. Closing a significant funding round in thistough financial climate is a noteworthy achievement."
MicroPhage CEO Steve Lundy added: "We have been validating our products inthe field and have received excellent feedback from laboratory professionalswho tested them against current methods. We are looking forward to completingour validation work and launching products, which leverage the tremendouspower of bacteriophage amplification technology for rapid bacterialidentification and susceptibility testing."
About MicroPhage
Based in Longmont, Colo. and privately held, MicroPhage, Inc. is workingto be a global leader in developing rapid diagnostics products for bacterialidentification and antibiotic susceptibility/resistance testing. Using itsbacteriophage-based amplification platform, the company has developed apatented process that is a product platform or engine for rapid, easy-to-use,inexpensive diagnostic tests. Its first products, expected in late 2009, willset a new standard for clinicians in MRSA identification and antibioticsusceptibility testing, and are designed to fit the demands of hospitals andlaboratories of all sizes. For further information, go tohttp://www.microphage.com.
SOURCE MicroPhage, Inc.
